The Genetic Technologies presentation, dated March 25, 2021, serves as a strategic update for a dual-listed public company (ASX and Nasdaq). The deck focuses on the transition from a single-test provider to a diversified 'geneType' platform covering oncology, cardiovascular disease, and metabolic health. Notably, the company outlines a three-pronged distribution strategy: B2B medical practitioners, consumer-initiated testing with medical supervision, and direct-to-consumer (DTC) models. With a market cap of approximately $81.15M AUD at the time of the deck, the presentation emphasizes a robus…
Key takeaways
- The company is dual-listed on the ASX and Nasdaq, reporting a market cap of $81.15M AUD / $61.01M USD as of March 2021 (Slide 17).
- Genetic Technologies utilizes a three-tier channel strategy: B2B Medical, Consumer Initiated Testing (CIT) with supervision, and Direct to Consumer (DTC) (Slide 7).
- The 'geneType' product for Breast and Colorectal Cancer is priced at AUD$349 / US$249 per test (Slide 7).
- A significant portion of the share registry (72%) is held by the Bank of Mellon as a custodian for US ADRs (Slide 17).
- The product pipeline is extensive, including TGA-approved tests for depression and COVID-19 risk assessment (Slide 9).
- The company reported a cash balance of $16.4M and nil debt as of December 31, 2020 (Slide 17).
- The vision is defined as a 'diversified genomics and AI driven preventative healthcare company' (Slide 5).
- The leadership team includes a mix of medical doctors (MBBS) and scientific PhDs, alongside corporate directors (Slide 19).
Genetic Technologies: A Public Market Strategy for Preventative Genomics
The Genetic Technologies (GTG) investor presentation from March 2021 is a classic example of a public company 'Meet the CEO' deck. Unlike early-stage startup decks that focus on problem-solution narratives, this presentation is designed to communicate scale, regulatory progress, and multi-channel distribution to a sophisticated investor base across the ASX and Nasdaq. The company positions itself as a diversified platform, moving beyond single-indication testing into a broad 'preventative health' ecosystem driven by AI and genomics.
Slide 1: Title and Branding
The cover slide introduces the 'geneType' branding, which serves as the consumer-facing identity for their genetic-based preventative health platform. The date, March 25, 2021, is clearly stated, along with the authorization by the Board of Genetic Technologies. The design is clean and corporate, utilizing a blue-toned palette that suggests a clinical and professional environment.
Slide 3: Our Vision - The Roadmap
This slide functions as an executive summary or table of contents, breaking the presentation into five pillars: Overview, Markets, Channels, Portfolio, and Capabilities. It sets the expectation that the company is focused on execution and 'game-changing' partnerships. The use of numbered pillars is a standard way to signal a structured corporate strategy to institutional investors.
Slide 5: Our Vision - The Mission Statement
The company defines its vision as "Empowering a healthier life!" and describes itself as a "diversified genomics and AI driven preventative healthcare company." The emphasis on being 'diversified' is key here; it signals to the market that the company is not a 'one-trick pony' reliant on a single test, but rather a platform capable of assessing risk for various serious diseases.
Slide 7: Our Channels – Pathways to Market
This is one of the most critical slides in the deck. It outlines a sophisticated three-channel distribution model:
Medical (B2B): Targeting practitioners, specialists, and surgeons. This includes reimbursable germline testing for BRCA and Lynch Syndrome. · Consumer Initiated Testing (CIT): This is a hybrid model where the consumer starts the process, but it remains under medical supervision via partners like InTeleLabs (US) and Phenix Health (Australia). Tests for Breast and Colorectal cancer are priced at $249 USD. · Direct to Consumer (DTC): A segment scheduled for development that will focus on non-medical tests like ancestry and gut microbiome.
This multi-pronged approach demonstrates an understanding of the different regulatory and sales hurdles inherent in the healthcare market.
Slide 9: Our Portfolio – Innovation Pipeline
Slide 9 provides a visual catalog of the company's product suite. It categorizes products by their status:
Released 2019/2020: Breast and Colorectal cancer risk assessment tests. · Distribution confirmed: COVID-19 SDR (Serious Disease Risk) test. · TGA Approved: A depression risk test (PREDICTIX by Taliaz). · Under Development: A wide array of Polygenic Risk Score (PRS) products including Prostate Cancer, Melanoma, Cardiovascular Disease, and Type 2 Diabetes.
The claim that these products will include ">70% of Morbidity" is a bold statement of market intent.
Slide 11: Our Portfolio – Expanding Divisions
This slide uses a hub-and-spoke diagram to show how Genetic Technologies sits at the center of various medical fields. It distinguishes between 'Existing divisions' (Oncology, COVID-19, Mental Health) and 'Emerging divisions' (CVD, Metabolic Diseases, Lifestyle, Pharmaco-genetics). This visual reinforces the 'platform' narrative, suggesting that the underlying technology is applicable across the entire spectrum of human health.
Slide 13: Summary and Outlook
Mirroring slide 3, this summary slide provides a final reinforcement of the five strategic pillars. It uses high-level descriptors like "Positioned for growth," "Targeted and deliberate," and "Aligned to execute." While light on new data, it serves to bookend the strategic portion of the presentation before moving into financials.
Slide 15: Closing
A simple 'Thank You' slide featuring a high-quality lifestyle image. This marks the transition from the strategic pitch to the formal corporate disclosures and team overview.
Slide 17: Corporate Overview
For a public company, this is the 'meat' of the deck. It provides essential financial data as of late 2020 and early 2021:
Dual Listing: ASX and Nasdaq. · Market Cap: $81.15M AUD / $61.01M USD. · Cash Position: $16.4M AUD with zero debt. · Share Registry: A significant 72% is held by the Bank of Mellon for US ADRs, indicating strong US investor participation.
The inclusion of 52-week trading ranges ($1.45 to $10.30 for the Nasdaq ADR) provides context on the stock's volatility and historical pricing.
Slide 19: Our Board and Management
The final slide introduces the leadership. The team is balanced between corporate governance (Peter Rubinstein, Nick Burrows) and deep medical/scientific expertise (Dr. Jerzy Muchnicki, Richard Allman). CEO Simon Morriss is positioned as the leader aligned for execution. The presence of multiple directors with legal and accounting designations (BEC, LLB, FCA) is typical for a dual-listed entity requiring rigorous compliance.
What Genetic Technologies Does Well
The deck excels at explaining a complex, multi-channel sales strategy. By breaking down B2B, CIT, and DTC, the company shows it understands that 'one size does not fit all' in medical diagnostics. The pipeline slide (Slide 9) is also highly effective, clearly distinguishing between what is currently generating revenue and what is future upside. For a public company, the transparency regarding their cash position and share registry is both required and well-presented, giving investors a clear view of the 'dry powder' available for R&D.
What Is Missing from the Deck
While the deck is strong on strategy and pipeline, it is notably thin on unit economics beyond a single price point for two tests. There is no data on customer acquisition costs (CAC) for the CIT or DTC channels, nor is there information on the sales cycle length for the B2B medical practitioner channel. Additionally, while the deck mentions 'AI-driven' technology, it does not explain the proprietary nature of their algorithms or how they maintain a competitive moat against larger genomic players like 23andMe or AncestryHealth.
What Other Founders Can Copy
Founders in the health-tech space should study Slide 7. Many startups struggle to decide between a 'pure' medical play and a 'pure' consumer play; Genetic Technologies shows how to bridge these worlds through a tiered channel strategy. The use of a 'hub-and-spoke' diagram (Slide 11) is also a great way to visualize platform potential without cluttering the slide with too much text. Finally, the clear categorization of a product pipeline by regulatory status (Released vs. TGA Approved vs. Under Development) is a best practice for any company operating in a regulated industry.
Frequently asked questions
- What is the primary business model for Genetic Technologies?
- Genetic Technologies operates as a diversified genomics platform. According to slide 7, they generate revenue through three distinct pathways: B2B sales to medical practitioners and specialists, Consumer Initiated Testing (CIT) through platforms like InTeleLabs and Phenix Health, and a planned Direct to Consumer (DTC) segment for non-medical genomic tests like ancestry and gut microbiome.
- What specific diseases does their testing cover?
- As shown on slide 9, their portfolio includes released tests for Breast Cancer and Colorectal Cancer. Their pipeline under development includes tests for COVID-19, BRCA Panel, Lynch Syndrome, Prostate Cancer, Melanoma, Cardiovascular Disease (CVD), and Type 2 Diabetes. They also offer a TGA-approved test for depression powered by Taliaz.
- How does the company handle medical supervision for consumer tests?
- For their CIT (Consumer Initiated Testing) segment, the company partners with telehealth providers. Slide 7 notes that they launched platforms in 2020 with medical supervision provided by InTeleLabs in the US and Phenix Health in Australia, ensuring a clinical layer exists between the consumer and the genomic data.
- What are the financial highlights mentioned in the deck?
- Slide 17 provides a snapshot of the company's public market standing as of March 2021. It lists a share price of 0.9c AUD and an ADR price of $4.06 USD. The company held $16.4M in cash with zero debt as of late 2020, supporting a market capitalization of roughly $61M USD.
- Who leads the company and what is their expertise?
- The management team, detailed on slide 19, is led by CEO Simon Morriss. The technical and clinical leadership includes Dr. Jerzy Muchnicki (Chief Medical Officer) and Richard Allman (Chief Scientific Officer, PhD in Microbiology). The board is chaired by Peter Rubinstein, who holds BEC and LLB degrees.
